Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

Tytuł:
Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Autorzy:
Lu CL; Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu branch, Hsin-Chu, Taiwan.
Lin YH
Wong WW
Lin HH
Ho MW
Wang NC
Hsieh SM
Sheng WH
Hung CC
Chen MY
Źródło:
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2011 Aug; Vol. 44 (4), pp. 258-64. Date of Electronic Publication: 2011 Jan 20.
Typ publikacji:
Clinical Trial; Journal Article
Język:
English
Imprint Name(s):
Publication: Feb. 2010- : Oxford, England : published by Elsevier for the Taiwan Society of Microbiology
Original Publication: Taipei, Taiwan : Chinese Society of Microbiology : Chinese Society of Immunology [and] : Infectious Diseases Society of the Republic of China,
MeSH Terms:
HIV-1*
Antiretroviral Therapy, Highly Active/*adverse effects
HIV Infections/*drug therapy
HIV Protease Inhibitors/*adverse effects
Hyperlipidemias/*chemically induced
Oligopeptides/*adverse effects
Pyridines/*adverse effects
Adult ; Antiretroviral Therapy, Highly Active/methods ; Atazanavir Sulfate ; CD4 Lymphocyte Count ; Chi-Square Distribution ; Female ; HIV Infections/blood ; HIV Protease Inhibitors/therapeutic use ; Humans ; Hyperlipidemias/blood ; Hyperlipidemias/virology ; Male ; Oligopeptides/therapeutic use ; Prospective Studies ; Pyridines/therapeutic use ; Treatment Outcome ; Triglycerides/blood
Substance Nomenclature:
0 (HIV Protease Inhibitors)
0 (Oligopeptides)
0 (Pyridines)
0 (Triglycerides)
4MT4VIE29P (Atazanavir Sulfate)
Entry Date(s):
Date Created: 20110429 Date Completed: 20111109 Latest Revision: 20151119
Update Code:
20240104
DOI:
10.1016/j.jmii.2010.08.003
PMID:
21524961
Czasopismo naukowe
Background: Prolonged exposure to combination antiretroviral therapy (CART) may result in hyperlipidemia and other metabolic complications. This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens.
Methods: In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who had developed hyperlipidemia after receiving CART that did not contain atazanavir were enrolled. Antiretroviral regimens were switched to regimens containing two nucleoside reverse-transcriptase inhibitors plus atazanavir 400 mg once daily or atazanavir 300 mg boosted with ritonavir 100 mg once daily. The lipid profiles, including total triglycerides, total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, CD4+ lymphocyte counts, and plasma HIV RNA load were determined every 3 months.
Results: Sixty-six patients with hyperlipidemia were enrolled. At the end of the study, triglyceride levels declined by 49.0% (p = 0.0002) and total cholesterol levels by 18.1% from baseline (p < 0.0001), whereas there were no significant changes observed for low-density lipoprotein- and high-density lipoprotein-cholesterol levels. Mean CD4 lymphocyte count increased from 465 cells/μL at baseline to 498 cells/μL at the end of the study, whereas the proportion of patients with undetectable plasma HIV RNA load increased from 73.1% to 81.7%. The regimens were well tolerated.
Conclusions: Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART.
(Copyright © 2011. Published by Elsevier B.V.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies